Union Budget 2025: Pharma industry applauds key provisions on drug accessibility, R&D boost
Budget provisions focus on customs duty exemptions, R&D funding, and healthcare infrastructure expansion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Immuneel Therapeutics
Bolstering India’s healthcare innovation in cancer, rare diseases: How Budget 2025 can make a…
Amit Mookim, CEO, Immuneel Therapeutics urges the govt to focus on establishing a strong compliance framework and expediting…
Pharma sector gears up for Budget 2025-26; urges for strong regulatory framework and faster approval…
Industry leaders share their expectations from the upcoming Union budget 2025-26. Increased allocation for R&D and…
Immuneel Therapeutics welcomes Amit Mookim as CEO
Mookim will focus on establishing partnerships with providers, practitioners, and public health, and delivering current CART…
Immuneel to offer affordable cell and gene therapy for cancer patients in India
In this video, Arun Anand, COO, Immuneel Therapeutics and Dr Bruce Levine, of the University of Pennsylvania Perelman School of…
Immuneel Therapeutics presents early data from India for Varnimcabtagene autoleucel at ASH Annual…
Seventy seven overall responses at day 90 in patients with multi-line treated leukemia and lymphoma who received Varnimcabtagene…
Immuneel sets up cell therapy development and production facility in Narayana Hrudayalaya Health…
The facility will currently focus on autologous cell therapies including CAR-T cell therapy for lymphomas and leukaemias
Immuneel, HCB and IDIBAPS enter into a collaboration and licensing agreement for CAR T cell therapy
Immuneel acquires exclusive license to CD19 CAR T product for the potential treatment of B cell malignancies for India